利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.021 秒)

    USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY
    2.
    发明申请
    USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY 审中-公开
    利多卡因胆碱（CBDV）在治疗急性胰腺炎中的应用

    公开(公告)号：US20150320698A1

    公开(公告)日：2015-11-12

    申请号：US14685753

    申请日：2015-04-14

    申请人： GW Pharma Limited ,  Otsuka Pharmaceutical Co., Limited

    发明人： Ben Whalley ,  Claire Williams ,  Gary Stephens ,  Takashi Futamura

    IPC分类号： A61K31/05 ,  A61K31/515 ,  A61K31/19 ,  A61K45/06

    摘要： This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

    摘要翻译： 本发明涉及植物大麻素大麻素（CBDV）和植物大麻素CBDV与四氢大麻素（THCV）和大麻二醇（CBD）的组合在治疗癫痫中的用途。 本发明还涉及植物大麻素CBDV与标准抗癫痫药（SAED）的组合的用途。 优选地，SAED是乙酰亚胺，丙戊酸盐或苯巴比妥之一。

    CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN
    3.
    发明申请
    CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN 有权
    用于治疗神经性疼痛的CANNABINOIDS

    公开(公告)号：US20140378539A9

    公开(公告)日：2014-12-25

    申请号：US14118563

    申请日：2012-05-18

    申请人： OTSUKA PHARMACEUTICAL CO. LIMITED ,  GWPHARMA LIMITED

    发明人： Sabatino Maione ,  Francesco Rossi ,  Geoffrey Guy ,  Colin Stott ,  Tetsuro Kikuchi

    IPC分类号： A61K31/352 ,  A61K31/05

    CPC分类号： A61K31/352 ,  A61K31/05

    摘要： The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.

    摘要翻译： 本发明涉及用于治疗神经性疼痛的大麻素。 优选地，大麻素是一种或多种以下物质的植物大麻素：大麻酚（CBG），大麻染料（CBC），大麻素（CBDV）或四氢大麻素（THCV）。 更优选植物大麻素从大麻植物提取物中分离和/或纯化。

    USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    7.
    发明申请
    USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY 有权
    使用一种或将PHYTO-CANNABINOIDS组合在治疗EPILEPSY

    公开(公告)号：US20150335590A1

    公开(公告)日：2015-11-26

    申请号：US14579061

    申请日：2014-12-22

    申请人： GW Pharma Limited ,  Otsuka Pharmaceutical Co., Limited

    发明人： Benjamin Whalley ,  Gary Stephens ,  Claire Williams ,  Geoffrey Guy ,  Stephen Wright ,  Tetsuro Kikuchi

    IPC分类号： A61K31/05 ,  A61K31/352

    CPC分类号： A61K31/05 ,  A61K31/352

    摘要： This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

    摘要翻译： 本发明涉及一种或多种大麻素用于治疗癫痫的用途，更具体地说涉及使用一种或大麻素的组合来治疗广泛性或部分性发作。 在一个实施方案中，其涉及大麻素THCV作为纯的或分离的化合物或作为其中显着量的任何THC天然存在的植物提取物的使用已被选择性地除去。 在另一个实施方案中，植物大麻素是CBD。

    Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
    9.
    发明授权
    Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) 有权

    公开(公告)号：US11318109B2

    公开(公告)日：2022-05-03

    申请号：US16709401

    申请日：2019-12-10

    申请人： GW Pharma Limited ,  Otsuka Pharmaceutical Co., Limited

    发明人： Benjamin Whalley ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

    IPC分类号： A61K31/05 ,  A61K36/185 ,  A61K31/352 ,  A61K31/045 ,  A61K31/353 ,  A61K45/06

    摘要： This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.